157
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Development and evaluation of chitosan microspheres for tetanus, diphtheria and divalent vaccines: a comparative study of subcutaneous and intranasal administration in mice

, , &
Pages 1175-1185 | Received 15 Jun 2011, Accepted 20 Aug 2011, Published online: 10 Oct 2011

References

  • Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002;78:15–24.
  • Almeida AJ, Alpar HO, Brown MR. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and guinea-pigs. J Pharm Pharmacol 1993;45:198–203.
  • Aguado MT. Future approaches to vaccine development: Single-dose vaccines using controlled-release delivery systems. Vaccine 1993;11:596–597.
  • Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y et al. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010;147:342–349.
  • Bowey K, Neufeld RJ. Systemic and mucosal delivery of drugs within polymeric microparticles produced by spray drying. BioDrugs 2010;24:359–377.
  • Shi L, Caulfield MJ, Chern RT, Wilson RA, Sanyal G, Volkin DB. Pharmaceutical and immunological evaluation of a single shot hepatitis B vaccine formulated with PLGA microspheres. J Pharm Sci 2002;91:1019–1035.
  • Singh M, Chakrapani A, O’Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007;6:797–808.
  • Jaganathan KS, Rao YU, Singh P, Prabakaran D, Gupta S, Jain A et al. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(d,l-lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm 2005;294:23–32.
  • Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W et al. Controlled release microparticles as a single dose diphtheria toxoid vaccine: Immunogenicity in small animal models. Vaccine 1998;16:346–352.
  • Dani BA, DeLuca PP. Preparation, characterization, and in vivo evaluation of salmon calcitonin microspheres. AAPS PharmSciTech 2001;2:22.
  • Kofuji K, Akamine H, Oshirabe H, Maeda Y, Murata Y, Kawashima S. Retention and release behavior of insulin in chitosan gel beads. J Biomater Sci Polym Ed 2003;14:1243–1253.
  • Kofuji K, Murata Y, Kawashima S. Sustained insulin release with biodegradation of chitosan gel beads prepared by copper ions. Int J Pharm 2005;303:95–103.
  • Ge YB, Chen DW, Xie LP, Zhang RQ. Optimized preparation of daidzein-loaded chitosan microspheres and in vivo evaluation after intramuscular injection in rats. Int J Pharm 2007;338:142–151.
  • Alonso MJ, Cohen S, Park TG, Gupta RK, Siber GR, Langer R. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm Res 1993;10:945–953.
  • Schwendeman SP, Costantino HR, Gupta RK, Tobio M, Chang AC, Alonso MJ et al. Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine. Dev Biol Stand 1996;87:293–306.
  • Zhu G, Mallery SR, Schwendeman SP. Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide). Nat Biotechnol 2000;18:52–57.
  • Johansen P, Men Y, Audran R, Corradin G, Merkle HP, Gander B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm Res 1998;15:1103–1110.
  • Illum L. (1998). Bioadhesive formulations for nasal peptide delivery. In: Mathiowitz E, Lehr CM, Chickering D (eds). Drug delivery-issues in fundamentals− Novel approaches and development. New York: Marcel Dekker, pp. 507–539.
  • van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001;52:139–144.
  • Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11:1186–1189.
  • Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001;217:183–191.
  • Illum L, Watts P, Fisher AN, Jabbal-Gill I, Davis SS. Novel chitosan based delivery systems for nasal administration of a LHRH-analogue. STP Pharma 2000;10:89–94.
  • Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999;178:55–65.
  • Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11:1358–1361.
  • Hames BD, Rickwood D. (1991). Gel Electrophoresis of Proteins: A Practical Approach. New York, USA: Oxford University Press.
  • Lee JH, Park TG, Lee YB, Shin SC, Choi HK. Effect of adding non-volatile oil as a core material for the floating microspheres prepared by emulsion solvent diffusion method. J Microencapsul 2001;18:65–75.
  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
  • el-Karamany RM. Production in Vero cells of an inactivated rabies vaccine from strain FRV/K for animal and human use. Acta Virol 1987;31:321–328.
  • Gohel MC, Sheth MN, Jani GK, Patel H. Design of chitosan microspheres containing diclofenac sodium. Ind J Pharm Sci 1994;56:210–214.
  • Manivannan R, Dhanaraj SA, Rao YU, Balasubramaniam A, Gowrishankar NL, Jawahar N et al. In vivo evaluation of single dose tetanus toxoid vaccine formulation with chitosan microspheres. Indian J Pharm Sci 2008;70:11–15.
  • Baxendalea AJ, Hooffa PV, Durrantb LG, Spendloveb I, Howdlea SM, Woods HM et al. Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology. Int J Pharm 2011;413:147–154.
  • Gupta KC, Jabrail FH. Glutaraldehyde and glyoxal cross-linked chitosan microspheres for controlled delivery of centchroman. Carbohydr Res 2006;341:744–756.
  • Chang AC, Gupta RK. Stabilization of tetanus toxoid in poly(dl-lactic-co-glycolic acid) microspheres for the controlled release of antigen. J Pharm Sci 1996;85:129–132.
  • Dineshkumar B, Dhanaraj SA, Santhi K Vijayan P, Chandrasekhar R. Single dose vaccine delivery system of tetanus toxoid formulation based on chitosan microspheres. Int J Adv Pharm Sci 2010;1:42–49.
  • Jameela SR, Kumary TV, Lal AV, Jayakrishnan A. Progesterone-loaded chitosan microspheres: A long acting biodegradable controlled delivery system. J Control Release 1998;52:17–24.
  • Prabaharan M, Mano JF. Chitosan-based particles as controlled drug delivery systems. Drug Deliv 2005;12:41–57.
  • Ponchel G, Touchard F, Duchene D, Pepas NA. Bioadhesive analysis of controlled-release systems, I: Fracture and interpenetration analysis in poly (acrylic acid)-containing systems. J Control Release 1987;5:129–141.
  • Amin M, Jaafari MR, Tafaghodi M. Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloids Surf B Biointerfaces 2009;74:225–229.
  • Department of Health and Human Services, Food and Drug Administration. Biological products; bacterial vaccines and toxoids; implementation of efficacy review; proposed rule. Federal Register 1985;50:51002–51117.
  • Abrahamian FM, Pollack CV Jr, LoVecchio F, Nanda R, Carlson RW. Fatal tetanus in a drug abuser with “protective” antitetanus antibodies. J Emerg Med 2000;18:189–193.
  • Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009;61:140–157.
  • Chaudhari M, Jadhav KR, Kadam VJ. An over view: Microspheres as a nasal drug delivery system. Int J Pharm Sci Rev Res 2010;5:8–17.
  • Niclas R, Ingvar S. Mucosal vaccination against diphtheria using starch microparticles as adjuvant for cross-reacting material (CRM197) of diphtheria toxin. Vaccine 2005;23:2775–2783.
  • Osth K, Strindelius L, Larhed A, Ahlander A, Roomans GM, Sjöholm I et al. Uptake of ovalbumin-conjugated starch microparticles by pig respiratory nasal mucosa. J Drug Target 2003;11:75–82.
  • Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun 1997;65:1716–1721.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.